These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27487367)

  • 1. Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine.
    Calvo Gómez C; Gómez-Huelgas R; Lima Ruiz J; Masmiquel Comas L; Michán Doña A; Zapatero Gaviria A
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):880-890. PubMed ID: 27487367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
    de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
    J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of liraglutide after three years of treatment.
    Ponzani P; Scardapane M; Nicolucci A; Rossi MC
    Minerva Endocrinol; 2016 Mar; 41(1):35-42. PubMed ID: 26878560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.
    Tassone F; Baffoni C; Gianotti L; Pellegrino M; Magro G; Cesario F; Maccario M; Borretta G
    Minerva Endocrinol; 2015 Dec; 40(4):331-2. PubMed ID: 25801016
    [No Abstract]   [Full Text] [Related]  

  • 8. In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
    Kauffman RP
    Ann Intern Med; 2022 May; 175(5):JC56. PubMed ID: 35500264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The antidiabetic drug liraglutide lowers risk of cardiac death].
    Overbeck P
    MMW Fortschr Med; 2016 Jun; 158(12):14. PubMed ID: 27323977
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
    Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
    G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.
    Hiramatsu T; Ozeki A; Asai K; Saka M; Hobo A; Furuta S
    Ther Apher Dial; 2015 Dec; 19(6):598-605. PubMed ID: 26556397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study.
    Gejl M; Starup-Linde J; Scheel-Thomsen J; Gregersen S; Vestergaard P
    Int J Cardiol; 2015 Jan; 178():292-6. PubMed ID: 25465309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.
    von Scholten BJ; Ørsted DD; Svendsen AL; Persson F; Rossing P
    J Diabetes Complications; 2015; 29(8):1146-51. PubMed ID: 26345339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.
    Daniels GH; Hegedüs L; Marso SP; Nauck MA; Zinman B; Bergenstal RM; Mann JF; Derving Karsbøl J; Moses AC; Buse JB; Tuttle RM;
    Diabetes Obes Metab; 2015 May; 17(5):477-86. PubMed ID: 25656058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.